Completed PHASE2 INTERVENTIONAL 2-arm NCT00108953

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.

Sponsor: Bayer

Conditions Carcinoma, Hepatocellular

Interventions Doxorubicin/Placebo Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin

Updated 8 times since 2017 Last updated: Oct 24, 2014 Started: Apr 30, 2005 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00108953, this PHASE2 trial focuses on Carcinoma, Hepatocellular and remains completed. Sponsored by Bayer, it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bebington, United Kingdom , Beverly Hills, United States , Birmingham, United Kingdom , Birmingham, United States , Buenos Aires, Argentina , Hackensack, United States , Hong Kong, Hong Kong , Kazan', Russia , Kirov, Russia , Krasnodar, Russia and 16 more locations